SCHEMBL2464620

SCHEMBL2464620

C=CCC1(O)CC(C2=C3C=NC=C[N+]3(Cl)C(c3cccc(OCc4ccccc4)c3)=N2)C1

nearest known ligand 0.33

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
BTK Q06187 1/20 0.32
PDE10A Q9Y233 1/20 0.32
NR1H2 P55055 1/20 0.32
MRGPRX4 Q96LA9 1/20 0.31
BCHE P06276 3/20 0.31
FAAH O00519 1/20 0.31
CNR2 P34972 1/20 0.31
IGF1R P08069 2/20 0.31
TNK2 Q07912 1/20 0.31
ALOX5 P09917 1/20 0.31
DHODH Q02127 1/20 0.31
F9 P00740 1/20 0.30
F10 P00742 1/20 0.30
ERN1 O75460 1/20 0.30
HDAC4 P56524 1/20 0.30
NAAA Q02083 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2461620 0.91 IGF1R (0.34) BTKPDE10AMRGPRX4BCHEFAAH
SCHEMBL2464664 0.90 CYP4F2 (0.34) PDE10ANR1H2MRGPRX4FAAHCNR2
SCHEMBL2459447 0.90 PDE10A (0.33) PDE10ANR1H2MRGPRX4FAAHCNR2
SCHEMBL2465897 0.88 F9 (0.34) PDE10ANR1H2MRGPRX4FAAHCNR2
SCHEMBL2460207 0.84 NR1H2 (0.35) PDE10ANR1H2MRGPRX4IGF1RTNK2
SCHEMBL2463346 0.83 IGF1R (0.35) PDE10ANR1H2MRGPRX4IGF1RTNK2
SCHEMBL2459426 0.82 BRD4 (0.36) PDE10ANR1H2MRGPRX4HDAC4
SCHEMBL2460369 0.82 IGF1R (0.38) PDE10ANR1H2MRGPRX4IGF1RTNK2
SCHEMBL2459990 0.81 IGF1R (0.39) PDE10ANR1H2IGF1RTNK2
SCHEMBL2464455 0.81 ERN1 (0.35) PDE10ANR1H2MRGPRX4IGF1RTNK2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1675860-B1 IMIDAZO[1,5-A]PYRAZINES AS TYROSINE KINASE INHIBITORS OSI PHARM INC (US) 2011-09-21 EP disclosed
US-20090181940-A1 Imidazopyrazine Tyrosine Kinase Inhibitors OSI PHARMACEUTICALS, INC. 2009-07-16 US disclosed
US-7459554-B2 Imidazopyrazine tyrosine kinase inhibitors OSI PHARMACEUTICALS, INC. (US) 2008-12-02 US disclosed
US-20080227788-A9 IMIDAZOPYRAZINE TYROSINE KINASE INHIBITORS BECK PATRICIA A 2008-09-18 US disclosed
US-20060084654-A1 Imidazopyrazine tyrosine kinase inhibitors ACERTA PHARMA B.V. (NL) 2006-04-20 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080227788-A9 IMIDAZOPYRAZINE TYROSINE KINASE INHIBITORS IGF1R, IRS1, IGFBP1 BTK 97/4885PDE10A 2449/4885NR1H2 2603/4885
US-20060084654-A1 Imidazopyrazine tyrosine kinase inhibitors IGF1R, IRS1, IGFBP1 BTK 97/4885PDE10A 2449/4885NR1H2 2603/4885
US-20090181940-A1 Imidazopyrazine Tyrosine Kinase Inhibitors IGF1R, IRS1, IGFBP1 BTK 97/4885PDE10A 2449/4885NR1H2 2603/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.